The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at a concentration of 0.05 µg/ml. IP: Use 1-10µg for 106 vanadate treated A431 cells. WB: Use at a concentration of 1ug/ml for AP/BCIP/NBT (MTT) detection; 0.1ug/ml for HRPO/ECL detection . Predicted molecular weight: 86 kDa. Dilution optimised using Chromogenic detection. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
FunctionKey dowstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. The majority of beta-catenin is localized to the cell membrane and is part of E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton.
Tissue specificityExpressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon.
Involvement in diseaseDefects in CTNNB1 are associated with colorectal cancer (CRC) [MIM:114500]. Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life. Defects in CTNNB1 are a cause of pilomatrixoma (PTR) [MIM:132600]; a common benign skin tumor. Defects in CTNNB1 are a cause of medulloblastoma (MDB) [MIM:155255]. MDB is a malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. Defects in CTNNB1 are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.
Sequence similaritiesBelongs to the beta-catenin family. Contains 12 ARM repeats.
Post-translational modificationsPhosphorylation by GSK3B requires prior phosphorylation of Ser-45 by another kinase. Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33. EGF stimulates tyrosine phosphorylation. Phosphorylation on Tyr-654 decreases CDH1 binding and enhances TBP binding. Ubiquitinated by the SCF(BTRC) E3 ligase complex when phosphorylated by GSK3B, leading to its degradation. Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent proteasomal degradation.
Cellular localizationCytoplasm. Nucleus. Cytoplasm > cytoskeleton. Cell junction > adherens junction. Cell junction. Cell membrane. Cytoplasmic when it is unstabilized (high level of phosphorylation) or bound to CDH1. Translocates to the nucleus when it is stabilized (low level of phosphorylation). Interaction with GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD inhibits nuclear localization.
Western blot - beta Catenin antibody [BDI770] (ab19452)
All lanes : Anti-beta Catenin antibody [BDI770] (ab19452) at 0.5 µg/ml
Lane 1 : Whole cell lysates of serum starved tumor A431 cells Lane 2 : Whole cell lysates of serum starved tumor SW480 cells Lane 3 : Whole cell lysates of serum starved tumor SW620 cells Lane 4 : Whole cell lysates of serum starved tumor HT29 cells Lane 5 : Whole cell lysates of serum starved tumor MCF7 cells Lane 6 : Whole cell lysates of serum starved tumor MDA-MB231 cells Lane 7 : Whole cell lysates of serum starved tumor T47D cells
Lysates/proteins at 20000 cells per lane.
Secondary A HRP-conjugated antibody Developed using the ECL technique
Predicted band size : 86 kDa
Exposure time : 30 seconds
References for Anti-beta Catenin antibody [BDI770] (ab19452)
This product has been referenced in:
Edwards CM et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood111:2833-42 (2008).
Read more (PubMed: 18094333) »